Melodia Therapeutics, Alivexis ink License Agreement for MOD-A

Melodia Therapeutics, Alivexis ink License Agreement for MOD-A

By, Admin 25 June 2024

Melodia Therapeutics, Alivexis ink license agreement for Cathepsin C inhibitor programme, MOD-A

Overview

Alivexis, Inc. and Melodia Therapeutics AG, a company established by Forty51 Ventures, announced that they have entered into an exclusive license agreement for the worldwide development, manufacturing, and commercialization of Alivexis’ MDI-0151, a novel Cathepsin C inhibitor with best-in-class potential. MDI-0151 is an innovative clinical candidate identified in Alivexis’ MOD-A discovery programme.

IND-enabling Activities for MDI-0151

  • Melodia will rapidly initiate IND-enabling activities for MDI-0151 to prepare for a phase 1/phase 2a study in various refractory inflammatory diseases caused by excessive activation of neutrophils, such as ANCA-associated Vasculitis and several other relevant diseases in the context of neutrophils.  
  • Patients suffering from these diseases have a high unmet medical need.

For Drug Discovery Research

Alivexis and Melodia will leverage their respective expertise in drug discovery research and development with the aim of obtaining clinical Proof of Concept in these indications.

Terms of the agreement

  • Under the terms of the agreement, Alivexis grants Melodia worldwide rights to develop, manufacture, and commercialize MDI-0151 and will receive from Melodia an upfront payment and development and sales milestone payments totalling up to approximately $275 million (JPY 42.7 billion), and will be entitled to receive royalties on net sales of any marketed product. 
  • In addition, Alivexis is eligible to receive a number of warrants to subscribe for Melodia’s common shares.

Words from CEO: Alivexis

  • S. Roy Kimura,D., CEO of Alivexis, commented on the deal: “I am pleased to announce the signing of our licensing and clinical partnership with Melodia for our MOD-A Cathepsin C inhibitor programme. This event marks a significant milestone for Alivexis and serves as validation of our drug discovery R&D team and platform, our proprietary pipeline of discovery programs, and our business model involving the use of our cutting-edge platform to accelerate clinical candidate discovery for diseases with high unmet need.”  
  • “This is the first of many licensing and collaboration agreements that we anticipate from our maturing portfolio of IND-ready candidate molecules in our pipeline and our unique and proven discovery platform. We are confident that the Melodia team will be able to take our candidate molecule through clinical trials and ultimately help many patients in need suffering from chronic inflammatory diseases.”

Statement from Forty51 Ventures

  • Melodia’s founding shareholder Forty51 Ventures commented on the deal: “We are extremely pleased to in-license and continue the development of MDI-0151. We consider that this asset from Alivexis has best-in-class, blockbuster potential.” 
  • “Melodia aims to develop the program in a variety of underserved indications in the field of immunology. Further announcements will follow shortly as Melodia advances this programme expeditiously.”

MDI-0151

  • MDI-0151 is a clinical candidate compound from the Alivexis’ discovery program MOD-A, focused on Cathepsin C inhibition. 
  • Cathepsin C, also known as dipeptidyl peptidase-1 (DPP-1), is an enzyme responsible for the activation of a group of proteases that play an important role in the destruction of tissues by neutrophils. 
  • As inhibition of Cathepsin C is believed to have little effect on the immune function of neutrophils, MDI-0151 may effectively treat various immune and inflammatory diseases while not compromising the immune system.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!